A study of two drug combinations for ovarian cancer that came back
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a common chemotherapy (Pegylated Liposomal Doxorubicin) plus an immunotherapy (Adebrelimab), with or without a bladder medication (Mirabegron), in people whose ovarian cancer has returned after initial treatment. The goal is to see if adding Mirabegron helps the other drugs work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian, fallopian tube, or primary peritoneal cancer confirmed by biopsy.
- You have received platinum-based chemotherapy before, and your cancer came back within 12 months of finishing that treatment.
- You are in fairly good health (able to care for yourself and up and about more than half the day).
- You have at least one tumor that can be measured on a scan.
- You are willing to provide a tumor tissue sample from a prior surgery or a new biopsy.
- You have not had certain immunotherapy drugs (like PD-1 or PD-L1 inhibitors) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called raludotatug deruxtecan for people with ovarian cancer that has come back. It's designed for those whose cancer is either sensitive or resistant to platinum chemotherapy, and who have had 1-3 prior treatments.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This trial tests combining surgery with an immunotherapy drug (sintilimab) for women whose ovarian cancer has returned after initial treatment. It aims to see if this approach can improve outcomes for people with specific tumor markers.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), a targeted therapy (bevacizumab), and a PARP inhibitor (fluzoparib) for ovarian cancer that came back at least 6 months after last platinum chemo. It aims to see if this mix helps control the cancer better.
This study tests a combination of two targeted drugs (mirvetuximab soravtansine and suvemcitug) for people with ovarian cancer that has come back after platinum-based chemotherapy and is no longer responding to it. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Ovarian Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.